The cardiac safety of aripiprazole treatment in patients at high risk for torsade: A systematic review with a meta-analytic approach

Psychopharmacology

Volumn 232, Issue 18, 2015, Pages 3297-3308

  Polcwiartek, Christoffer ^a,b   Sneider, Benjamin ^a   Graff, Claus ^b   Taylor, David ^c   Meyer, Jonathan ^d   Kanters, Jørgen K ^e,f   Nielsen, Jimmi ^a,b  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b AALBORG UNIVERSITY   (Denmark)

^c SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Aripiprazole; Brugada syndrome; QTc interval; Sudden cardiac death; Torsades de Pointes

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; DELAYED RECTIFIER POTASSIUM CHANNEL; FLUPHENAZINE; HALOPERIDOL; LORAZEPAM; OLANZAPINE; PEROSPIRONE; PERPHENAZINE; PLACEBO; QUETIAPINE; RISPERIDONE; SULPIRIDE; ZIPRASIDONE; NEUROLEPTIC AGENT; POTASSIUM;

ABSENCE OF SIDE EFFECTS; BRUGADA SYNDROME; DRUG SAFETY; EPIDEMIOLOGICAL MONITORING; HIGH RISK PATIENT; HUMAN; META ANALYSIS; NONHUMAN; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; SUDDEN CARDIAC DEATH; SYSTEMATIC REVIEW; TORSADE DES POINTES; CHEMICALLY INDUCED; CONGENITAL MALFORMATION; ELECTROCARDIOGRAPHY; HEART; HEART ARRHYTHMIA; HEART MUSCLE CONDUCTION SYSTEM; HEART RATE; LONG QT SYNDROME; RISK FACTOR; SAFETY;

ANTIPSYCHOTIC AGENTS; ARIPIPRAZOLE; ARRHYTHMIAS, CARDIAC; DEATH, SUDDEN, CARDIAC; ELECTROCARDIOGRAPHY; HEART; HEART CONDUCTION SYSTEM; HEART RATE; HUMANS; LONG QT SYNDROME; POTASSIUM; RISK FACTORS; SAFETY; TORSADES DE POINTES;

EID: 84939257476     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-015-4024-9     Document Type: Review

References (43)

1. Bloch Thomsen PE, Joergensen RM, Kanters JK et al (2005) Phase 2 reentry in man. Hear Rhythm 2:797-803
2. Blom MT, Cohen D, Seldenrijk A et al (2014) Brugada syndrome ECG is highly prevalent in schizophrenia. Circ Arrhythmia Electrophysiol 7:384-391
3. Carstairs SD, Williams SR (2005) Overdose of aripiprazole, a new type of antipsychotic. J Emerg Med 28:311-313
4. Christoffersen RK, Vestergård LD, Høimark L, Vesterby A (2011) Eosinophilic myocarditis and sudden unexpected death in a younger patient treated with antipsychotics. Ugeskr Læger 173:2799-2800
5. Correll CU, Nielsen J (2010) Antipsychotic-associated all-cause and cardiac mortality: what should we worry about and how should the risk be assessed? Acta Psychiatr Scand 122:341-344
6. Darbar D, Yang T, Churchwell K et al (2006) Unmasking of Brugada syndrome by lithium. Circulation 112:1527-1531
7. Fanoe S, Kristensen D, Fink-Jensen A et al (2014) Risk of arrhythmia induced by psychotropic medications: a proposal for clinical management. Eur Heart J 35:1306-1315
8. Gerhard T, Huybrechts K, Olfson M et al (2014) Comparative mortality risks of antipsychotic medications in community-dwelling older adults. Br J Psychiatry 250:44-51
9. Goldenberg I, Moss AJ, Zareba W (2006) QT interval: how to measure it and what is "normal". J Cardiovasc Electrophysiol 17:333-336
10. Graff C, Andersen MP, Xue JQ et al (2009a) Identifying drug-induced repolarization abnormalities from distinct ECG patterns in congenital long QT syndrome: a study of sotalol effects on T-wave morphology. Drug Saf 32:599-611
11. Graff C, Matz J, Christensen EB et al (2009b) Quantitative analysis of T-wave morphology increases confidence in drug-induced cardiac repolarization abnormalities: evidence from the investigational IKr inhibitor Lu 35-138. J Clin Pharmacol 49:1331-1342
12. Huang X-P, Mangano T, Hufeisen S et al (2010) Identification of human ether-à-go-go related gene modulators by three screening platforms in an academic drug-discovery setting. Assay Drug Dev Technol 8:727-742
13. ICH (2005) The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E14/E14-Guideline.pdf. Accessed 26 Apr 2015
14. Kanters JK, Haarmark C, Vedel-Larsen E et al (2008) T(peak)T(end) interval in long QT syndrome. J Electrocardiol 41:603-608
15. Kim SY, Song MK, Kim M-S et al (2014) Sex-related differences in the effect-site concentration of remifentanil for preventing QTc interval prolongation following intubation in elderly patients with a normal QTc interval. Drugs Aging 31:695-702
16. Kongsamut S, Kang J, Chen X-L et al (2002) A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. Eur J Pharmacol 450:37-41
17. Leucht S, Cipriani A, Spineli L et al (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382:951-962
18. Levine M, Bosak A, Yee B, Tran A (2013) Carbamazepine induced seizures and ventricular dysrhythmias. Clin Toxicol 51:653-654
19. Lu HR, Remeysen P, Somers K et al (2001) Female gender is a risk factor for drug-induced long QT and cardiac arrhythmias in an in vivo rabbit model. J Cardiovasc Electrophysiol 12:538-545
20. Mallikaarjun S, Salazar DE, Bramer SL (2004) Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol 44:179-187
21. Meyer JM, Davis VG, Goff DC et al. (2008) Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res. 101:273-286
22. Nelson S, Leung JG (2013) Torsades de Pointes after administration of low-dose aripiprazole. Ann Pharmacother 47, e11
23. Nielsen J (2012) QTc prolongation and clozapine: fact or artefact? Aust N Z J Psychiatry 46:793-794
24. Nielsen J (2011) The safety of atypical antipsychotics: does QTc provide all the answers? Expert Opin Drug Saf 10:341-344
25. Nielsen J, Andersen MP, Graff C et al (2010a) The effect of sertindole on QTD and TPTE. Acta Psychiatr Scand 121:385-388
26. Nielsen J, Correll CU, Manu P, Kane JM (2013) Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided? J Clin Psychiatry 74:603-613, quiz 613
27. Nielsen J, Graff C, Hardahl T et al (2009) Sertindole causes distinct electrocardiographic T-wave morphology changes. Eur Neuropsychopharmacol 19:702-707
28. Nielsen J, Graff C, Kanters JK et al (2011) Assessing QT interval prolongation and its associated risks with antipsychotics. CNS Drugs 25:473-490
29. Nielsen J, Skadhede S, Correll CU (2010b) Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. Neuropsychopharmacology 35:1997-2004
30. Otsuka (2014) Abilify® (aripiprazole) prescribing information. http://www.otsuka-us.com/Documents/Abilify.PI.pdf. Accessed 26 Apr 2015
31. Porthan K, Viitasalo M, Jula A et al (2009) Predictive value of electrocardiographic QT interval and T-wave morphology parameters for all-cause and cardiovascular mortality in a general population sample. Hear Rhythm 6:1202-1208, 1208.e1
32. Potkin SG, Saha AR, Kujawa MJ et al (2003) Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 60:681-690
33. Raschi E, Poluzzi E, Godman B et al (2013) Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe. PLoS One 8, e81208
34. Ray WA, Chung CP, Murray KT et al (2009) Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 360:225-235
35. Ries R, Sayadipour A (2014) Management of psychosis and agitation in medical-surgical patients who have or are at risk for prolonged QT interval. J Psychiatr Pract 20:338-344
36. Shah RR (2004) Drug-induced QT interval prolongation: regulatory perspectives and drug development. Ann Med 36 sup. 1:47-52.
37. Sicouri S, Antzelevitch C (2008) Sudden cardiac death secondary to antidepressant and antipsychotic drugs. Expert Opin Drug Saf 7:181-194
38. Silvestre JS, Prous JR (2007) Comparative evaluation of hERG potassium channel blockade by antipsychotics. Methods Find Exp Clin Pharmacol 29:457-465
39. Straker DA, Shapiro PA, Muskin PR (2006) Aripiprazole in the treatment of delirium. Psychosomatics 47:385-391
40. Sugiyama A, Satoh Y, Hashimoto K (2001) In vivo canine model comparison of cardiohemodynamic and electrophysiological effects of a new antipsychotic drug aripiprazole (OPC-14597) to haloperidol. Toxicol Appl Pharmacol 173:120-128
41. Tran-Johnson TK, Sack DA, Marcus RN et al (2007) Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 68:111-119
42. Vieta E, Franco C (2008) Advances in the treatment of mania: aripiprazole. Actas Esp Psiquiatr 36:158-164
43. Windfuhr K, Turnbull P, While D et al (2011) The incidence and associated risk factors for sudden unexplained death in psychiatric in-patients in England and Wales. J Psychopharmacol 25:1533-1542